


**Supplementary Figure S1. Cell quality control, marker gene expression pattern of the eight cell subsets. (Related to Figure 1).**

A: Before quality control, each sample's nFeature\_RNA, nCount\_RNA and percent. mitochondrial genes.

B: After quality control, each sample's nFeature\_RNA, nCount\_RNA and percent. mitochondrial genes.

C: Heatmap illustrating top ten highly expressed marker genes of each cell subsets.



**Supplementary Figure S2. Tumor cells subsets and marker genes expression. (Related to Figure 2)**

**A:** UMAP plot showing the fourteen epithelial cells clusters.

**B:** UMAP plot shows that the 14 epithelial cells clusters were derived from 7 PC cells clusters, 3 LC cells clusters and 4 BC cells clusters.

**C:** Violin plot suggests that the fourteen epithelial cells clusters had elevated copy number variation (CNV) score compared to T cells.


**D:** The TCGA/GTEX data analysis validated that PPAP2A expression increased in prostate adenocarcinoma tissues compared to the normal prostate tissues., T: tumor; N: normal.

**E:** Immunohistochemical (IHC) staining demonstrated that CHI3L1 expression in primary lung

adenocarcinoma (LUAD). CHI3L1 is moderately expressed in the cytoplasm of primary LAUD cells and barely in the tumor stroma. Scale = 40  $\mu$ m.

**F:** The TCGA/GTEx data analysis validated that CHI3L1 expression increased in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissues compared to the normal lung tissues. T: tumor; N: normal.

**G:** The TCGA/GTEx data analysis validated that ESR1 expression increased in breast invasive carcinoma tissues compared to the normal breast tissues. T: tumor; N: normal.







**Supplementary Figure S3.** Marker genes expression of the myeloid cells subsets **(Related to Figure 3).**

**A:** Dot plot showing the marker genes expression of the myeloid cells subsets.

**B:** Dot plot showing the marker genes expression of M1 and M2-TAMs.


**C:** Immunofluorescence staining further verified that M2-TAMs were widely expressed in LC-BoM tissues. TAMs were marked with CD68. M2-TAMs were further marked with CD163.

**A****B**

**Supplementary Figure S4.** Cell communications in prostate cancer (PC)-bone metastasis (BoM) and breast cancer (BC)-bone metastasis (BoM). **(Related to Figure 8).**

**A:** Bone metastatic PC tumor cells as senders highly express macrophage migration inhibitory factor (MIF). SPP1<sup>+</sup> TAMs as receiver highly express its receptors CD74 and CXCR4.

**B:** Bone metastatic BC tumor cells as senders highly express amyloid precursor protein (APP). MMP19<sup>+</sup> TAMs as receiver highly express its receptors CD74 and TREM2.



**Supplementary Figure S5.** The impact of MMP19 on the number and function of CD8<sup>+</sup> T cells (Related to Figure 8). Recombinant human MMP19 reduced the proportion of CD8<sup>+</sup> T (A). Recombinant human MMP19 decreased the TNF- $\alpha$  level secreted by CD8<sup>+</sup> T cells in the supernatant (B).